Brain Cancer News and Research

RSS

There are two main types of brain cancer. Primary brain cancer starts in the brain. Metastatic brain cancer starts somewhere else in the body and moves to the brain. Brain tumors can be benign, with no cancer cells, or malignant, with cancer cells that grow quickly. Also called glioma, meningioma.

Study shows strong correlation between brain dominance and the ear used for cell phone

If you're a left-brain thinker, chances are you use your right hand to hold your cell phone up to your right ear, according to a newly published study from Henry Ford Hospital in Detroit.

17 May 2013

NW Bio starts Phase III clinical trial with DCVax-L for brain cancer at King's College Hospital in UK

Northwest Biotherapeutics, a biotechnology company developing DCVax-L personalized immune therapies for solid tumor cancers, today announced that its Phase III clinical trial with DCVax-L for brain cancer has been initiated at King's College Hospital in the UK.

17 May 2013

Novel drug may increase the effectiveness of radiation therapy for brain cancer

A novel drug may help increase the effectiveness of radiation therapy for the most deadly form of brain cancer, report scientists at Virginia Commonwealth University Massey Cancer Center. In mouse models of human glioblastoma multiforme (GBM), the new drug helped significantly extend survival when used in combination with radiation therapy.

15 May 2013

Drug resistant brain tumors: an interview with Prof. Mischel, Ludwig Institute for Cancer Research and Prof. Bensinger, University of California

In cancer, mutations in proteins that control cell growth are common, leading to unrestrained cellular proliferation and tumor formation.

9 May 2013

Study shows efficacy of PEGylated liposomal doxorubicin in intracranial model of breast cancer

Breast cancer brain metastases present a challenge to clinicians because there are few systemic therapies capable of crossing the blood-brain barrier to control the disease.

2 May 2013

Neuralstem gets approval from FDA for dosing cohort patients in NSI-189 Phase Ib in MDD treatment

Neuralstem, Inc. announced that it has received approval from the Food and Drug Administration (FDA) to begin dosing the third and final cohort of patients in its ongoing Phase Ib to test the safety of NSI-189 in the treatment of major depressive disorder (MDD).

26 Apr 2013

GBM brain cancer patient treated with DCVax-L celebrates 10th anniversary of cancer-free survival

Northwest Biotherapeutics, a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, announced today that Brad Silver, an All American swimming and water polo athlete who was diagnosed with Glioblastoma multiforme brain cancer in late 2002, and was treated with DCVax-L in March of 2003, just celebrated the 10th anniversary of his continued cancer-free survival.

19 Apr 2013

Gold nano-bullets to defeat cancer

Cutting edge research into an experimental therapy that deploys nano-particles of gold in the fight against cancer earned an Alberta high school student, 16, top national honours today in the 2013 "Sanofi BioGENEius Challenge Canada" (SBCC).

11 Apr 2013

Study reports role of cytochrome c oxidase as prognostic marker in GBM patients' tumor tissues

Researchers may have discovered a more accurate way to predict how long patients with the deadliest form of brain cancer will live, according to an analysis by researchers from the University of Alabama at Birmingham published today in the journal PLOS ONE.

11 Apr 2013

DelMar Pharmaceuticals reports positive results from VAL-083 Phase I/II clinical trial in patients with GBM

DelMar Pharmaceuticals, Inc. today announced additional positive interim data from an ongoing Phase I/II clinical trial of VAL-083 in patients with recurrent glioblastoma multiforme (GBM) or progressive secondary brain tumor.

11 Apr 2013

Lynch syndrome and cancer risk: an interview with Prof. Ellen Kampman, Wageningen University

Lynch syndrome is one of the inherited cancer syndromes characterized by the development of colorectal cancer, endometrial cancer and other cancers at an early age.

10 Apr 2013

Nano-sized EVs play role in cancer growth and survival

The recent discovery of circulating "nano-sized extracellular vesicles" (EVs) carrying proteins and nucleic acids derived from brain tumors may lead to exciting new avenues for brain cancer diagnosis, monitoring, and treatment, according to a special article in the April issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

9 Apr 2013

Exosome profiling of mRNAs and miRNAs in serum samples presented at AACR meeting

Exosome Diagnostics, a leading developer of biofluid-based molecular diagnostics for use in personalized medicine, today announced that the company is presenting a late-breaking abstract at the AACR Annual Meeting 2013, in Washington D.C.

9 Apr 2013

Researchers explore how blocking EGFR changes signaling in glioblastoma cells

Proteins that control cell growth are often mutated in cancer, and their aberrant signaling drives the wild proliferation of cells that gives rise to tumors. One such protein, the epidermal growth factor receptor, fuels a wide variety of cancers-including a highly malignant brain cancer known as glioblastoma.

9 Apr 2013

Mammalian target of rapamycin (mTOR) pathway: an interview with Dr. Paul Mischel, Ludwig Institute for Cancer Research

The mammalian target of rapamycin, mTOR is a central integrator of the cell that coordinates growth factor receptor signaling with energy and nutrient status to control a wide array of activities, including the regulation of cellular proliferation and survival.

9 Apr 2013

Certain brain tumors develop drug resistance by exploiting normal cellular signaling pathways

Proteins that control cell growth are often mutated in cancer, and their aberrant signaling drives the wild proliferation of cells that gives rise to tumors.

9 Apr 2013

Patent covering methods of treating ALS receives notice of allowance

Neuralstem, Inc. announced today that it received a notice of allowance for patent application 12/404,841. This patent covers methods for treating amyotrophic lateral sclerosis (ALS or Lou Gehrig 's disease) with expanded spinal cord stem cells, including NSI-566.

6 Apr 2013

Neurological researchers study promising new treatment for deadly brain tumors

A promising new treatment for deadly brain tumors taken orally with minimal side effects is being studied by neurological researchers at Rush University Medical Center, Chicago.

28 Mar 2013

SLU researcher studies effect of bitter melon extract on treating cancer

A Saint Louis University researcher has received a $39,425 grant from the Lottie Caroline Hardy Charitable Trust to continue her research on treating cancer with a natural substance -- the extract taken from a vegetable that is part of her diet.

24 Mar 2013

AANS, CNS urge Congress to restore Medicare payments for stereotactic radiosurgery

he American Association of Neurological Surgeons and Congress of Neurological Surgeons are urging Congress to restore Medicare hospital outpatient payment rates for Cobalt-60-based stereotactic radiosurgery to those in place prior to the enactment of the American Taxpayer Relief Act.

21 Mar 2013

Brain Cancer News and Research

Further Reading

Study shows strong correlation between brain dominance and the ear used for cell phone

NW Bio starts Phase III clinical trial with DCVax-L for brain cancer at King's College Hospital in UK

Novel drug may increase the effectiveness of radiation therapy for brain cancer

Drug resistant brain tumors: an interview with Prof. Mischel, Ludwig Institute for Cancer Research and Prof. Bensinger, University of California

Study shows efficacy of PEGylated liposomal doxorubicin in intracranial model of breast cancer

Neuralstem gets approval from FDA for dosing cohort patients in NSI-189 Phase Ib in MDD treatment

GBM brain cancer patient treated with DCVax-L celebrates 10th anniversary of cancer-free survival

Gold nano-bullets to defeat cancer

Study reports role of cytochrome c oxidase as prognostic marker in GBM patients' tumor tissues

DelMar Pharmaceuticals reports positive results from VAL-083 Phase I/II clinical trial in patients with GBM

Lynch syndrome and cancer risk: an interview with Prof. Ellen Kampman, Wageningen University

Nano-sized EVs play role in cancer growth and survival

Exosome profiling of mRNAs and miRNAs in serum samples presented at AACR meeting

Researchers explore how blocking EGFR changes signaling in glioblastoma cells

Mammalian target of rapamycin (mTOR) pathway: an interview with Dr. Paul Mischel, Ludwig Institute for Cancer Research

Certain brain tumors develop drug resistance by exploiting normal cellular signaling pathways

Patent covering methods of treating ALS receives notice of allowance

Neurological researchers study promising new treatment for deadly brain tumors

SLU researcher studies effect of bitter melon extract on treating cancer

AANS, CNS urge Congress to restore Medicare payments for stereotactic radiosurgery

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News